5月27日，新上市的派格生物医药-B（02565.HK）股价表现不佳，盘中大跌15%，引发市场关注。该公司今日在港交所挂牌上市，但开盘即告破发，开盘价为13港元，较发行价15.6港元下跌16.67%。
派格生物医药-B此前公布的招股结果显示，公司香港公开发售部分获得743.78倍超额认购，认购热度极高。公司共发行1928.35万股股份，每手500股，最终定价为每股15.6港元，募集资金净额约2.32亿港元。
尽管公开发售反应热烈，但派格生物医药-B上市首日的股价表现却令投资者失望。分析人士指出，这可能反映了投资者对生物科技股的谨慎态度，以及对公司短期盈利能力的担忧。作为一家专注于慢性病创新疗法研发的生物科技公司，派格生物医药-B的核心产品PB-119虽已接近商业化阶段，但投资者可能需要更多时间来评估公司的长期发展前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.